Boston Trust Walden Corp Purchases Shares of 10,645 IDEXX Laboratories, Inc. $IDXX

Boston Trust Walden Corp acquired a new stake in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm acquired 10,645 shares of the company’s stock, valued at approximately $5,981,000.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Beacon Investment Advisory Services Inc. raised its holdings in IDEXX Laboratories by 11.9% during the 4th quarter. Beacon Investment Advisory Services Inc. now owns 62,951 shares of the company’s stock valued at $42,588,000 after buying an additional 6,710 shares during the last quarter. Nordea Investment Management AB grew its holdings in IDEXX Laboratories by 114.1% in the 4th quarter. Nordea Investment Management AB now owns 16,597 shares of the company’s stock worth $11,283,000 after acquiring an additional 8,845 shares during the last quarter. Procyon Advisors LLC purchased a new position in shares of IDEXX Laboratories in the fourth quarter valued at about $1,966,000. Diversified Trust Co. increased its position in shares of IDEXX Laboratories by 223.5% in the fourth quarter. Diversified Trust Co. now owns 4,199 shares of the company’s stock valued at $2,841,000 after acquiring an additional 2,901 shares during the period. Finally, Mirabella Financial Services LLP increased its position in shares of IDEXX Laboratories by 156.2% in the third quarter. Mirabella Financial Services LLP now owns 4,401 shares of the company’s stock valued at $2,806,000 after acquiring an additional 2,683 shares during the period. Institutional investors own 87.84% of the company’s stock.

IDEXX Laboratories Stock Performance

NASDAQ:IDXX opened at $557.80 on Friday. The company has a 50-day moving average price of $555.31 and a 200-day moving average price of $609.16. IDEXX Laboratories, Inc. has a 12 month low of $506.91 and a 12 month high of $769.98. The company has a current ratio of 1.12, a quick ratio of 0.82 and a debt-to-equity ratio of 0.19. The stock has a market cap of $44.00 billion, a price-to-earnings ratio of 41.08, a P/E/G ratio of 3.05 and a beta of 1.55.

IDEXX Laboratories (NASDAQ:IDXX) last announced its earnings results on Tuesday, May 5th. The company reported $3.47 earnings per share for the quarter, beating analysts’ consensus estimates of $3.41 by $0.06. IDEXX Laboratories had a net margin of 24.63% and a return on equity of 70.87%. The firm had revenue of $1.14 billion for the quarter, compared to analyst estimates of $1.12 billion. During the same quarter in the previous year, the firm posted $2.91 EPS. The company’s revenue for the quarter was up 14.3% compared to the same quarter last year. IDEXX Laboratories has set its FY 2026 guidance at 14.450-14.900 EPS. Equities analysts predict that IDEXX Laboratories, Inc. will post 14.68 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of analysts have recently weighed in on the stock. UBS Group dropped their target price on shares of IDEXX Laboratories from $730.00 to $640.00 and set a “neutral” rating for the company in a report on Tuesday, April 28th. Stifel Nicolaus reduced their price target on IDEXX Laboratories from $775.00 to $675.00 and set a “buy” rating on the stock in a report on Tuesday, March 31st. Citigroup began coverage on IDEXX Laboratories in a research report on Wednesday, April 15th. They set a “neutral” rating and a $650.00 price target for the company. Weiss Ratings raised IDEXX Laboratories from a “hold (c)” rating to a “hold (c+)” rating in a research report on Thursday, June 25th. Finally, Wall Street Zen upgraded IDEXX Laboratories from a “hold” rating to a “buy” rating in a report on Saturday, June 13th. Seven analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $751.00.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.